NCT01810913 2026-04-17
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
National Cancer Institute (NCI)
Phase 2/3 Recruiting
Clinical Trials
8 trialsRecruiting × Squamous Cell Carcinoma of Head and Neck × Radiotherapy, Intensity-Modulated × Clear all
NCT04671667 2026-04-17
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT07219212 2026-04-13
LUMIRAY
Johnson & Johnson Enterprise Innovation Inc.
Phase 1 Recruiting
NCT07423078 2026-04-13
WOLF
University of Pittsburgh
Phase 2 Recruiting
NCT06532279 2026-04-03
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
NRG Oncology
Phase 2 Recruiting
NCT02734537 2026-03-23
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
Eastern Cooperative Oncology Group
Phase 2 Recruiting
NCT06914999 2025-10-22
Comparing an Investigational Scan (F-18 NaF PET/CT) to Standard of Care Imaging (F-18 FDG PET/CT) for Evaluating Vascular Complications in Patients Receiving Radiation Therapy for Head and Neck Cancer
Emory University
Phase EARLY_PHASE1 Recruiting
NCT05213884 2023-05-06
The Efficacy of Induction and Adjuvant Camrelizumab Combined With Chemoradiation for LA-HNSCC
Chongqing University Cancer Hospital
Phase 2 Recruiting